Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin

Health and Quality of Life Outcomes

Volumn 14, Issue 1, 2016, Pages

  Mehta, Neel ^a   Bucior, Iwona ^b   Bujanover, Shay ^b   Shah, Rajiv ^c   Gulati, Amitabh ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Depomed Inc   (United States)

^c ST FRANCIS HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gabapentin; Gastroretentive; Neuropathic pain; Postherpetic neuralgia; Quality of life; Sleep

Indexed keywords

GABAPENTIN; PLACEBO; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DELAYED RELEASE FORMULATION;

ADULT; AGED; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GENERAL MENTAL DISEASE ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; MIDDLE AGED; PAIN ASSOCIATED SLEEP INTERFERENCE; PAIN INTENSITY; PATIENT CARE; PATIENT GLOBAL IMPRESSION OF CHANGE; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP QUALITY; VISUAL ANALOG SCALE; ADOLESCENT; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG EFFECTS; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; PHASE 2 CLINICAL TRIAL; PREVALENCE; SLEEP; THERAPEUTIC USE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINES; ANALGESICS; CYCLOHEXANECARBOXYLIC ACIDS; DELAYED-ACTION PREPARATIONS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MANAGEMENT; PAIN MEASUREMENT; PREVALENCE; QUALITY OF LIFE; SLEEP; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85007482941     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/s12955-016-0456-0     Document Type: Article

References (29)

1. Gharibo C, Kim C. Neuropathic pain of postherpetic neuralgia. Pain Med News. 2011;9:84-92.
2. Pickering G, Leplege A. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Pract. 2011;11:397-402.
3. Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss. 2012;20:441-51.
4. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on healthrelated quality of life: review and implications. Neurology. 2007;68:1178-82.
5. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182:1731-6.
6. Roehrs T, Roth T. Sleep and pain: interaction of two vital functions. Semin Neurol. 2005;25:106-16.
7. Odrcich M, Bailey JM, Cahill CM, Gilron I. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain. 2006;120:207-12.
8. Lautenbacher S, Kundermann B, Krieg JC. Sleep deprivation and pain perception. Sleep Med Rev. 2006;10:357-69.
9. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374-85.
10. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain. 2007;23:15-22.
11. Roehrs TA, Harris E, Randall S, Roth T. Pain sensitivity and recovery from mild chronic sleep loss. Sleep. 2012;35:1667-72.
12. Chhangani BS, Roehrs TA, Harris EJ, Hyde M, Drake C, Hudgel DW, et al. Pain sensitivity in sleepy pain-free normals. Sleep. 2009;32:1011-7.
13. Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev. 2004;8:119-32.
14. Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther. 2013;35:612-23.
15. Rauck RL, Irving GA, Wallace MS, Vanhove GF, Sweeney M. Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Pain Symptom Manage. 2013;46:219-28.
16. Gupta A, Li S. Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over. Drugs Aging. 2013;30:999-1008.
17. Backonja MM, Canafax DM, Cundy KC. Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Med. 2011;12:1098-108.
18. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-42.
19. Rice ASC, Maton S, Group PNS. Gabapentin in posterpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94:215-24.
20. Kantor D, Panchal S, Patel V, Bucior I, Rauck R. Treatment of postherpetic neuralgia with gastroretentive gabapentin: interaction of patient demographics, disease characteristics, and efficacy outcomes. J Pain. 2015;16:1300-11.
21. Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig. 2010;30:765-76.
22. Sang CN, Sathyanarayana R, Sweeney M, Investigators DMS. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain. 2013;29:281-8.
23. Markley HG, Dunteman ED, Kareht S, Sweeney M. Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). Clin J Pain. 2015;31:58-65.
24. Farrar JD, Young JPJ, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-58.
25. Ostelo RW, Deyo RA, Stratford P, Waddell G, Croft P, Von Korff M, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine. 2008;33:90-4.
26. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105-21.
27. Belgrade MJ. Following the clues to neuropathic pain. Distribution and other leads reveal the cause and the treatment approach. Postgrad Med. 1999;106:127-32. 35-40.
28. Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146:238-44.
29. Perez-Lloret S, Rojas GM, Menoni MC, Ruiz G, Velasquez C, Rodriguez H, et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course. Clin Neuropharmacol. 2012;35:21-4.